. First, IGFs promote incorporation of 35-sulphate into cartilage, hence 'sulphation' factor (Salmon & Daughaday, 1957) . Secondly, they mediate the mitogenic activity of serum (Pierson & Temin, 1972) and medium conditioned by rat hepatocytes (multiplication stimulating activity, MSA; Dulak & Temin. 1973) . Thirdy. IGFs have insulin-like activity which is not inhibited by anti-insulin antibodies (non-suppressive insulin-like activity, NSILA: Froesch et al., 1963) . Sequence analysis revealed that these functions are subserved by two main peptide: IGF-I, also known as somatomedin-C (Klapper et al.. 1983 ) and IGF-II. of which the rat form is MSA ( Rinderknecht & Humbel. 1978 ; Marquardt et al.. 1981) . The IGF terminology is now preferred as there is no somatomedin designation for IGF-II (Daughaday et al.. 1987) .
IGF-I (70 residues, MW 7649) and IGF-II (67 residues.
MW 7471) are single chain peptides with around 70% sequence homology, and 50% homology with pro-insulin.
Mature IGFs have A and B domains where the homology with proinsulin is highest, a C-peptide domain which has no sequence homology with proinsulin. and a carboxyterminal D domain (Daughaday & Rotwein. 1989) . The IGF-I gene is located on chromosome 12q, and the IGF-II gene is on chromosome llp, contiguous with the insulin gene (Barreca & Minuto. 1989 ). In the mouse, the IGF-II gene is imprinted. that is. there is a difference in expression between the maternal and paternal genes. Specifically, it is the paternal IGF-II gene which is active (Willison. 1991) . IGF-I is synthesised by the liver and also by other viscera including kidney and lung (D'Ercole et al., 1984) . Hepatic synthesis, which largely determines serum levels, is regulated by growth hormone (GH) and also varies with liver function and nutritional status (Underwood et al., 1986; Zapf & Froesch. 1986 ). In endocrine-sensitive tissues. IGF-I gene expression may be regulated by hormones other than GH. Notably in rat uterus, IGF-I expression is enhanced by oestrogen, and is repressed to a small extent by GH (Murphy & Friesen, 1988) . In vitro, IGF-I is a potent mitogen for normal cells including chondrocytes and other mesenchymal derivatives (Clemmons & Van Wyk, 1981) . In vivo, IGF-I has acute insulin-like anabolic effects on adipose tissue, muscle and liver (Zapf & Froesch, 1986; Guler et al.. 1987) . However its most important physiological role is as the primary regulator of growth, especially of mesenchymal tissues including bone and cartilage (Schoenle et al., 1982; Van Buul-Offers et al.. 1986; Mathews et al., 1988) . IGF-II has metabolic and mitogenic effects experimentally, but its physiological function is unclear. Serum concentrations are less dependent on GH. and it causes less growth promotion in hypophysectomised animals (Schoenle et al., 1983 and muscle, and also in the CNS (Han et al.. 1987 : Brice et al.. 1989 . The suggestion that IGF-lI may be important for foetal growth is supported by the demonstration of growth deficiency in foetal mice carrying an IGF-II gene disrupted by targetting (DeChiara et al., 1990) .
IGFs bind to two types of cell surface IGF receptor and also cross-react with the human insulin receptor (HIR; Rech- ler & Nissley. 1986 (Massague & Czech. 1982) . The m and P subunits are generated by cleavage of a transmembrane precursor polypeptide (Lammers et al.. 1989) . The type I receptor binds IGF-I with high affinity, has 2-3 times lower affinity for IGF-II and 100 times lower affinity for insulin (Czech, 1989) . Sequence analysis of the type I IGF receptor and HIR shows homology which is most pronounced (84%) in the tyrosine kinase domains (Ullrich et al.. 1986 ). Both receptors can mediate acute metabolic and longer-term mitogenic effects. In vitro effects on glucose transport appear similar. but chimeric receptors possessing the cytoplasmic domain of the IGF receptor are 10 times more active in stimulating DNA synthesis and are more stable (Lammers et al., 1989) . It is this receptor which probably mediates the mitogenic effects of both IGFs and insulin (Van Wyk et al.. 1985) . Other in vivo differences in the actions of IGF-I and insulin may be attributable to the tissue distribution of their receptors (Czech, 1989) . The type II IGF receptor is a single chain monomer of MW 250,000. It has much higher affinity for IGF-II than IGF-I, and negligible affinity for insulin. Like the IGF-II gene, the murine IGF-II receptor gene is imprinted, but here it is the maternal gene which is active (Willison, 1991) . The type II receptor is present on virtually all cell types. and in cultured cells has been shown to mediate calcium influx and synthesis of DNA and glycogen (Massague & Czech, 1982 (Morgan et al.. 1987; Oshima et al., 1988) . Proteins containing mannose-6-phosphate include lysosomal enzymes such as procathepsin-D. and pro-TGFP (Rochefort et al., 1987; Czech, 1989) . It now seems that these two distinct functions are indeed subserved by the same receptor molecule, suggesting that growth regulating receptors can interact both with carbohydrates and growth factors (MacDonald et al., 1988; Roth, 1988 (Cascieri et al.. 1988a : Bagley et al.. 1989 : Ross et al.. 1989 ). For further information on the biochemistn-and function of IGFs. see reviews by Barreca and Minuto (1989 (Kaleko et al.. 1990 ). In cultured human melanoma cells, the type I receptor has been shown to mediate a highly potent motility response to IGFs and insulin. an effect which could enhance the potential for local and distant spread (Stracke et al.. 1989) . IGFs and insulin also stimulate motility in human breast, bladder and ovarian cancer cell lines, and the concentrations required for optimal migration appear lower than for maximal growth stimulation (Kohn et al.. 1990 (Goldstein et al.. 1989 ) and growth of normal human bronchial epitheHal cells (Seigfried, 1989) . Thus IGFs seem to be important in lung development. and are also implicated in growth regulation of lung tumours.
Primary lung tumours possess IGF-I binding sites as shown by autoradiography. with the highest density of receptors in squamous cancers and small cell lung cancer (SCLC: Shigematsu et al.. 1990) . lodinated ligand binding studies on cultured SCLC cells demonstrate two classes of IGF-I binding site of high (Kd 0.1-1.1 n.M) and lower (3-4nM) affinity (Nakanishi et al.. 1988 : Macaulay et al.. 1990 ). These receptors are functional. because exogenous IGF-I causes a mitogenic response in SCLC cells (Jaques et al.. 1988 : Nakanishi et al.. 1988 Macaulay et al.. 1988a and ) and non-SCLC (Siegfried. 1989) . Immunoreactive IGF-I is detectable in primary lung tumour tissue including non-SCLC (squamous and adenocarcinoma) and SCLC. at higher levels than in normal lung (Minuto et al.. 1986 : Macaulay et al.. 1988a . Immunohistochemistrv shows strong staining for IGF-I especially in cases of squamous lung cancer (Shigimatsu et al.. 1990) . Immunoreactive IGF-I is also detectable in extracts of cultured SCLC and non-SCLC cells and their conditioned media (Jaques et al.. 1988 : Macaulay et al.. 1988a . Siegfried. 1989 ). Western blot analysis shows a 16.000 MW band consistent with an incompletely processed IGF-I precursor (Nakanishi et al.. 1988 ). However. IGF-I levels are not raised in the serum of lung cancer patients and levels are unrelated to bulk of disease or response to treatment. Thus IGF-I is not a marker for disease activity, presumably reflecting the relatively small contribution of the tumour compared with hepatic IGF-I production (Macaulay et al.. 1988b ). Indeed circulating IGF-I levels may be low in association with poor nutritional status or abnormal liver function (Minuto et al.. 1986 ). In addition to IGF-I-like peptides, lung cancer cells can also synthesise IGF BPs. Cross-linking studies with -'5I-IGF-I or -II show that SCLC conditioned medium contains IGF BPs with MW of 24-32,000 (Jaques et al.. 1989) . Low MW BPs (25-30.000) are elevated in the serum of lung cancer patients compared with normal controls (Reeve et al.. 1990 ).
Thus there is good evidence that lung cancer cells produce IGF-I and IGF BPs. express IGF binding sites and exhibit a mitogenic response to exogenous IGF-I. suggesting that IGF-I can function as an autocrine growth factor for lung cancer. presumably the alpha subunit of the type I receptor. In low serum or serum-free medium, growth of cultured breast cancer cells is stimulated by IGF-I 5 nM. which generates a greater response than that to optimal concentrations of oestradiol (E2) or epidermal growth factor (EGF). Higher concentrations of IGF-II and insulin are required to produce a similar effect, supporting the suggestion that IGFs and insulin exert their mitogenic effects via the type I IGF receptor (Furlanetto & DiCarlo, 1984 : Pollak et al.. 1988 : Peyrat e-at.. 1988 Foekens et at.. 1989a; Cullen et at. 1990 : Osborne & Arteaga. 1990 ).
Cultured cells and fresh tumour specimens also express IGF-I-like activity and levels are 2 10 times higher in oestrogen receptor (ER) negative than in ER positive cell lines (Huff et al.. 1986; Foekens et al., 1989a) . Northern analysis using a cDNA probe to IGF-I reveals a pattern of multiple cross-hybridising mRNA bands in breast cancer cell lines.
The pattern is more complex than in normal human liver (Rotwein, 1986) , and is very similar to human foetal tissues (Han et al., 1987) (Osborne & Arteaga, 1990 (Katzenellenbogen & Normon, 1990 Fagin & Melmed, 1987) . They are also implicated in growth regulation of tumours derived from these tissues (see Table II (Yashiro et al., 1989) , hepatoma (Hartshorn et al., 1989) (Reeve et al., 1985; Scott et al., 1985) . Although IGF-II mRNA is over-expressed up to 30-fold, immunoreactive IGF-II is expressed at only 4-6 times higher levels than normal kidney. This suggests regulation at the translational level, the presence of non-functional mRNA, or that IGF-II is being degraded or secreted more rapidly than normal (Haselbacher et al., 1987) . The IGF-II gene is located on chromosome llp, near the Wilms' tumour susceptibility gene.
There is a single case report of a Wilms' tumour patient with a structural alteration in an IGF-II gene, but there is no other evidence of IGF-II gene amplification or rearrangement (Reeve et al., 1985; Irminger et al., 1989 Beckwith, 1963; Wiedemann, 1964) . This is a rare foetal over-growth syndrome characterised by exomphalos, macroglossia, gigantism, hypoglycaemia and visceromegaly. Around 12% of these patients develop embryonal neoplasia including Wilms', hepatoblastoma and rhabdomyosarcoma. Henry et al. (1991) Jaques et al., 1988 Macaulay et al., 1988a Minuto et al., 1986 Nakanishi et al., 1988 Reeve et al., 1990 Shigematsu et al., 1990 Siegfried, 1989 Furnaletto & DiCarlo, 1984 Huff et al., 1986 Peyrat et al., 1988 Pollak et al., 1988 De (Jordan, 1990) .
The long-acting somatostatin analogue octreotide (SMS 201-995) has been shown to reduce circulating levels of various peptides including IGF-I in patients with acromegaly, carcinoid and other neuroendocrine tumours, and this is associated in some cases with measurable tumour regression (Kvols et al., 1986; Lamberts et al., 1987; Schally, 1988) . Pollak et al. (1989) treated eight patients with non-endocrine solid tumours of exocrine pancreas, ovary, breast, kidney and colon. Octreotide therapy was accompanied by a significant fall in basal and arginine-stimulated growth hormone secretion and in serum IGF-I levels, but no data were given on tumour response. In 20 patients with SCLC, octreotide treatment was associated with a fall in circulating IGF-I levels in most patients, but there were no objective clinical responses (Macaulay et al., 1991) . At present it is not clear whether it will be possible to suppress circulating levels of a potent mitogen such as IGF-I to the extent that the local tissue concentration becomes limiting for tumour growth.
There seems more promise in attempts to inhibit the actions of IGFs by blocking their interaction with the receptor. A monoclonal antibody to IGF-I, SM1.2 (Russell et al., 1984) has been shown to inhibit the growth of SCLC and non-SCLC cells in vitro (Minuto et al., 1988; Macaulay et al., 1990) . However, this approach is unlikely to be successful in vivo, because of the substantial serum reservoir of IGF-I. In theory a membrane bound target is preferable, because there is unlikely to be a significant serum reservoir which would impair the localisation of treatment to the tumour. In many of the experimental systems described above, the mitogenic effects of IGFs and insulin appear to be mediated via the type I IGF receptor, and therefore this has been the treatment target chosen by most groups. A monoclonal antibody to the type I receptor, aIR3 (Kull et al., 1983) has been shown to inhibit the growth of breast cancer cells in vitro (Rohlik et al., 1987; Pollak et al., 1988; Freed & Herington, 1989; Arteaga & Osborne, 1989; Cullen et al., 1990 (Arteaga et al., 1989) . In addition, aIR3 has been shown to inhibit the growth in vitro of human SCLC (Nakanishi et al., 1988; Macaulay et al., 1990) , pancreatic carcinoma (Ohmura et al., 1990 ) and neuroblastoma (El-Badry et al., 1989 There are two further ways of blocking the interaction of IGFs with receptors. The polyanionic compound suramin has been shown to inhibit the mitogenic effects of PDGF and EGF, and has recently been shown to interfere with the interaction between IGF-I and the type I receptor in cultured osteosarcoma cells (Pollak & Richard, 1990) . This is associated with inhibition of IGF-I stimulated proliferation of these cells in vitro, an effect which is reversed by removal of the drug, suggesting a cytostatic rather than a cytotoxic effect. Finally, structure-activity studies indicate that distinct domains in the IGF-I molecule are responsible for type I receptor binding and mitogenic activiy (Cascieri et al., 1988b , Chen et al., 1988 . Therefore it might be possible to synthesise an analogue of IGF-I which retains high affinity type I receptor binding, but which does not activate the receptor, thus producing an antagonistic effect on growth.
T _mour kypoglycaemis
This rare metabolic manifestation of IGF activity has been described in patients with mesenchymal tumours including mesothelioma, fibrosarcoma, rhabdomyosarcoma, leiomyosarcoma, liposarcoma and haemangiopercytoma. It can also occur in cases of hepatoma, adrenocortical carcinoma, renal carcinoma, Wilms', and cancers of the breast, prostate and cervix. The tumours are often large and slow growing and two thirds are in the abdomen or retroperitoneum, the remainder being intrathoracic. Patients are characteristically elderly, and present with symptoms of hypoglycaemia, especially confusion, usually preceding the diagnosis of the tumour. Symptoms may be severe, requiring glucose infusion, and resolve after surgical resection of the tumour (Daughaday, 1989) .
For some time it has been recognised that insulin is not the cause of hypoglycaemia complicating non-islet cell tumours. Recent molecular studies have confirmed earlier suggestions that this phenomenon is mediated by IGF production by the tumour. Northern analysis and RNase protection assay of three tumours (pleural mesothelioma, thoracic and pelvic fibrosarcomas) revealed elevated levels of IGF-II mRNA. There were high circulating levels of immunoreactive IGF-II, most of which was in a high MW (9,000-15,000) form (Daughaday et al., 1988; Ron et al., 1989; Daughaday, 1990) . Other studies have confirmed over-expression of IGF-II mRNA, without IGF-H gene amplification or rearrangement (Lowe et al., 1989) . It is suggested that IGF-II causes hypoglycaemia by stimulating glucose uptake into peripheral tissues (fat and muscle) and possibly also into the tumour. In addition, a negative feed-back effect on growth hormone secretion impairs the hepatic response to hypoglycaemia, and suppresses serum IGF-I levels (Axelrod & Ron, 1988) . However, several groups have been unable to show any elevation of circulating IGF-II in patients with tumour hypoglycaemia (Widmer et al., 1983; Merimee, 1986) . One patient with a para-ovanan sarcoma, hypoglycaemia and high tumour IGF-II mRNA had suppressed serum IGF-I and IGF-II, presumably as a consequence of the hypoglycaemia, and neither the tumour cyst fluid nor the primary tissue culture conditioned medium had high IGF-II levels (Schofield et al., 1989) . This over-expression of mRNA without apparent increase in peptide production is analogous to the situation described in Wilms' (Haselbacher et al., 1987) .
Two aspects of IGF biology may explain the apparent lack of correlation between the degree of hypoglycaemia and measured levels of circulating IGF-II. Firstly, several studies have demonstrated the presence of high MW incompletely processed pro-IGF-II in tumours and sera of hypoglycaemic patients with hepatoma and fibrosarcoma but not in euglycaemic patients with hepatoma (Daughaday et al.. 1988 and Shapiro et al., 1990) . This 'big IGF-II is fully reactive with the IGF-II receptor (Daughaday et al.. 1988 ) but has lower affinity for serum IGF BPs than authentic IGF-II (Shapiro et al., 1990) . Secondly. the 150.000 MW IGF BP complex appears to be absent from the serum of some patients with tumour hypoglycaemia, replaced in some cases with 110.000 and 60.000 MW complexes (Daughaday & Kapachia. 1989 
